Pages that link to "Q48333460"

The following pages link to Differential effect of chronic dopaminergic treatment on dopamine D1 and D2 receptors in the monkey brain in MPTP-induced parkinsonism (Q48333460):

Displayed 31 items.

• Pharmacological Treatments Inhibiting Levodopa-Induced Dyskinesias in MPTP-Lesioned Monkeys: Brain Glutamate Biochemical Correlates (Q26852311) ‎ (← links)
• Priming for l-dopa-induced dyskinesia in Parkinson's disease: a feature inherent to the treatment or the disease? (Q34044620) ‎ (← links)
• The primate model of Parkinson's disease: its usefulness, limitations, and importance in directing future studies (Q34120740) ‎ (← links)
• Pathophysiology of levodopa-induced dyskinesia: potential for new therapies (Q34325365) ‎ (← links)
• Inversion of dopamine responses in striatal medium spiny neurons and involuntary movements (Q35932567) ‎ (← links)
• Induction of dopamine D3 receptor expression as a mechanism of behavioral sensitization to levodopa (Q36085612) ‎ (← links)
• Comparative Ultrastructural Analysis of D1 and D5 Dopamine Receptor Distribution in the Substantia Nigra and Globus Pallidus of Monkeys (Q37342898) ‎ (← links)
• Focal striatal dopamine may potentiate dyskinesias in parkinsonian monkeys (Q37398168) ‎ (← links)
• Absolute abundances and affinity states of dopamine receptors in mammalian brain: A review (Q37838858) ‎ (← links)
• Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation. (Q37924629) ‎ (← links)
• Non-human primate models of PD to test novel therapies (Q39229450) ‎ (← links)
• Chronic exposure to dopamine agonists affects the integrity of striatal D2 receptors in Parkinson's patients (Q41566638) ‎ (← links)
• Subthalamic deep brain stimulation differently alters striatal dopaminergic receptor levels in rats (Q41582688) ‎ (← links)
• Levodopa or D2 agonist induced dyskinesia in MPTP monkeys: correlation with changes in dopamine and GABAA, receptors in the striatopallidal complex (Q42277740) ‎ (← links)
• Dopamine and nicotinic receptor binding and the levels of dopamine and homovanillic acid in human brain related to tobacco use. (Q42540026) ‎ (← links)
• Effects of L-DOPA-therapy on dopamine D2 receptor mRNA expression in the striatum of MPTP-intoxicated parkinsonian monkeys (Q42552539) ‎ (← links)
• Dopamine D(1) receptor expression in human basal ganglia and changes in Parkinson's disease (Q43540752) ‎ (← links)
• The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. (Q44668514) ‎ (← links)
• Increased D1 dopamine receptor signaling in levodopa-induced dyskinesia. (Q45130529) ‎ (← links)
• Upregulation of striatal D2 receptors in the MPTP-treated vervet monkey is reversed by grafts of fetal ventral mesencephalon: an autoradiographic study (Q46580727) ‎ (← links)
• Upregulation of dopamine D2 receptors in dopaminergic drug-naive patients with Parkin gene mutations (Q46971688) ‎ (← links)
• Striatal dopaminergic markers in dementia with Lewy bodies, Alzheimer's and Parkinson's diseases: rostrocaudal distribution (Q48147364) ‎ (← links)
• A proton magnetic resonance spectroscopy study of the striatum and cerebral cortex in Parkinson's disease (Q48199227) ‎ (← links)
• Dopaminergic activities in the human striatum: rostrocaudal gradients of uptake sites and of D1 and D2 but not of D3 receptor binding or dopamine (Q48229063) ‎ (← links)
• Differential vulnerability of dopamine receptors in the mouse brain treated with MPTP. (Q48241892) ‎ (← links)
• Nigrostriatal dopaminergic activities in dementia with Lewy bodies in relation to neuroleptic sensitivity: comparisons with Parkinson's disease. (Q48361936) ‎ (← links)
• Continuous or pulsatile chronic D2 dopamine receptor agonist (U91356A) treatment of drug-naive 4-phenyl-1,2,3,6-tetrahydropyridine monkeys differentially regulates brain D1 and D2 receptor expression: in situ hybridization histochemical analysis (Q48678048) ‎ (← links)
• L-DOPA produces strong induction of c-fos messenger RNA in dopamine-denervated cortical and striatal areas of the common marmoset (Q64767857) ‎ (← links)
• Early institution of bromocriptine in Parkinson's disease inhibits the emergence of levodopa-associated motor side effects. Long-term results of the PRADO study (Q71605674) ‎ (← links)
• Differential regulation of striatal dopamine D(1) and D(2) receptors in acute and chronic parkinsonian monkeys (Q73190000) ‎ (← links)
• Expression of D(3) receptor messenger RNA and binding sites in monkey striatum and substantia nigra after nigrostriatal degeneration: effect of levodopa treatment (Q73897941) ‎ (← links)